Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

About this update from Veru Inc.

[{"type":"image","alt":"Veru Inc.","displaySize":"","headline":null,"caption":"Veru Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":214,"url":"https://media.zenfs.com/en/globenewswire.com/0a5f4ba487ea74752851101a11482743"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/mewu0yec4GXSU1yHV5yukA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0a5f4ba487ea74752851101a11482743","width":300,"height":214},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/mewu0yec4GXSU1yHV5yukA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0a5f4ba487ea74752851101a11482743","width":300,"height":214}},"lazy":false},{"type":"text","content":"--Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on track for interim analysis first quarter calendar year 2027—","length":158,"tagName":"p"},{"type":"text","content":"--Company to host conference call and webcast today at 8:00 a.m. ET—","length":68,"tagName":"p"},{"type":"text","content":"MIAMI, FL, May 13, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced financial results for its fiscal 2026 second quarter ended March 31, 2026, and provided a corporate update.","length":348,"tagName":"p"},{"type":"text","content":""We are extremely pleased with the progress of the enrollment of the Phase 2b PLATEAU clinical trial to evaluate the effect of enobosarm 3mg on total body weight, fat mass, lean mass, physical function, bone mineral density and safety in older patients who have obesity and receiving a semaglutide GLP-1 RA treatment for weight reduction. We are on track for presenting the results of the interim analysis which is expected in Q1 calendar year 2027,” said Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer of Veru Inc.","length":546,"tagName":"p"},{"type":"text","content":"Veru Obesity Program – Study of Enobosarm in combination with GLP-1 RA for higher quality weight reduction","length":106,"tagName":"p"},{"type":"text","content":"Phase 2b PLATEAU Clinical Study – Actively enrollingPhase 2b PLATEAU clinical trial is a double-blind, placebo-controlled ...

More updates from Veru Inc.